University of Chinese Academy of Sciences , Beijing 100049, P. R. China.
College of Chemistry & Environmental Science, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education, Chemical Biology Key Laboratory of Hebei Province, Hebei University , Baoding 071002, P. R. China.
ACS Appl Mater Interfaces. 2017 May 24;9(20):16900-16912. doi: 10.1021/acsami.7b03877. Epub 2017 May 10.
Vitamin E derivatives possess many essential features for drug-delivery applications, such as biocompatibility, stability, improvement of water solubility of hydrophobic compounds, anticancer activity, and the ability to overcome multidrug resistance (MDR). Herein, vitamin E derivatives are used to overcome MDR through a combined P-glycoprotein (P-gp) inhibition and mitochondrial impairment strategy. A novel nanomicellar drug-delivery system as a carrier for doxorubicin (DOX) was developed, in which d-α-tocopheryl polyethylene glycol 1000 succinate was used as a P-gp inhibitor, α-tocopheryl succinate was introduced as a mitochondrial disrupting agent, and d-α-tocopheryl polyethylene glycol 2000 succinate was used as the main building block of micelles. The optimal ratio between the components of the nanocarrier was determined. The resultant DOX-loaded mixed micelles exhibited a suitable size of 52.08 nm, high drug-loading encapsulation efficiency (>98%), high stability, and pH-dependent drug release. In vitro experiments demonstrated a significantly increased cytotoxic activity of DOX-loaded mixed micelles against resistant MCF-7/Adr cells (45-fold higher than DOX after 48 h of treatment). In vivo studies revealed superior antitumor efficiency with less cardio- and hepatotoxicities of DOX-loaded micelles compared with that of free DOX. These results highlight that the developed DOX-loaded mixed micelles have a promising potential to overcome MDR in chemotherapy for clinical usage.
维生素 E 衍生物具有许多适用于药物输送应用的重要特性,如生物相容性、稳定性、提高疏水性化合物的水溶性、抗癌活性以及克服多药耐药性(MDR)的能力。在此,通过联合使用 P 糖蛋白(P-gp)抑制和线粒体损伤策略,维生素 E 衍生物被用于克服 MDR。开发了一种新型的纳米胶束药物输送系统作为多柔比星(DOX)的载体,其中 d-α-生育酚聚乙二醇 1000 琥珀酸酯被用作 P-gp 抑制剂,α-生育酚琥珀酸酯被引入作为线粒体破坏剂,d-α-生育酚聚乙二醇 2000 琥珀酸酯被用作胶束的主要构建块。确定了纳米载体各组分的最佳比例。所得的 DOX 负载混合胶束表现出适宜的粒径(52.08nm)、高载药包封效率(>98%)、高稳定性和 pH 依赖性药物释放。体外实验表明,DOX 负载混合胶束对耐药 MCF-7/Adr 细胞的细胞毒性活性显著增强(治疗 48 小时后比 DOX 高 45 倍)。体内研究表明,与游离 DOX 相比,DOX 负载胶束具有更好的抗肿瘤效率和更低的心肝毒性。这些结果表明,开发的 DOX 负载混合胶束具有克服化疗中 MDR 的巨大潜力,有望在临床上应用。